Improving patient access and retention in clinical trials for CROs and pharma
ICC London have announced the official launch of their patient access and retention department (PAR), which specialises in assisting pharmaceutical companies and CROs with recruiting and retaining patients for clinical trials.
Improving patient access and
retention in clinical trials for CROs and pharma 14th April 2016, London, UK
ICC London have announced the official launch of their patient access and
retention department (PAR), which specialises in assisting pharmaceutical
companies and CROs with recruiting and retaining patients for clinical trials. Over
25,000 trails are published every year - but only 55% meet patient
recruitment targets.
By
utilising the increasingly connected world in which patients now live, ICC have
been creating prototype tools that help with the costly and time-consuming
issue of patient access and recruitment.
Over
the past year, ICC have already trialled this offering with CROs - to great success. Their services
have helped hit patient trial quotas, months before target deadline.
Now,
these pioneering digital solutions are available to all their clients to help improve
target numbers in a cost-effective way.
Otis
Baker, MD at ICC HC, commented: “We are excited to have built an innovative
in-house team and a truly unique offering. By making the most of today’s
digital landscape, we look forward to helping CRO and pharma companies with
their clinical trial recruitment.”
For more
information about our PAR services please contact otis.baker@icc-hc.com
ICC London have announced the official launch of their patient access and retention department (PAR), which specialises in assisting pharmaceutical companies and CROs with recruiting and retaining patients for clinical trials.
ICC HC
ICC London has announced the launch of their in-house technology centre, The Garage, which is to host innovation labs for pharma clients across Europe. ICC HC